* Ocuphire Pharma Inc OCUP.OQ OCUP.O is expected to show
a
rise in quarterly revenue when it reports results on March 22
(estimated).
* The Farmington Hills Michigan-based company is expected
to
report revenue of $29.445 million, according to the mean
estimate from 5 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Ocuphire Pharma Inc
is
for earnings of 97 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $22, above its last closing price of $3.77.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.29 -0.29 -0.22 Beat 23.7
Jun. 30 2022 -0.33 -0.33 -0.25 Beat 24.7
Mar. 31 2022 -0.34 -0.35 -0.35 Met 0
Dec. 31 2021 -0.20 -0.29 -0.35 Missed -22.1
Sep. -0.39 -0.36 -0.25 Beat 30.2
30 2021
Jun. 30 2021 -0.36 -0.36 -0.52 Missed -43.1
Mar. 31 2021 -0.70 -0.71 -0.47 Beat 34
Dec. 31 2020 -0.42 -0.42 -5.18 Missed -1,133
.3
This summary was machine generated March 20 at 12:04 GMT. All
figures in US dollars unless otherwise stated